HCA Healthcare faces securities fraud investigation after cutting 2026 profit forecast, stock drops nearly 7%.

HCA Healthcare announced a significant reduction in its full-year 2026 profit guidance due to an unfavorable payer mix that reduced revenue by about $400 million in Q2. Following this announcement, HCA's stock price fell nearly 7%. Pomerantz LLP is investigating whether HCA and some of its executives engaged in securities fraud or other illegal business practices related to this financial disclosure. Investors affected are encouraged to contact the law firm for potential class action participation.